


Source: Date: outsourcing-pharma.com Tuesday 1, March 2016



Reproduced by Gorkana under licence from the NLA (newspapers), CLA (magazines), FT (Financial Times/ft.com) or other copyright owner. No further copying (including printing of digital cuttings), digital reproduction/forwarding of the cutting is permitted except under licence from the copyright owner. All FT content is copyright The Financial Times Ltd.



Source: Date: outsourcing-pharma.com Tuesday 1, March 2016

Keyword:

Veeva Systems

California-headquartered Veeva is due to announce its full year financials for fiscal 2016 today. In its previous results announcement the firm reported that the revenue contribution made by its regulatory, trial and data management businesses increased.

CFO Tim Cabral said: "For the first time, our non-CRM offerings accounted for more than 25% of total revenues in the quarter. Our success across the board stems from the reputation we've developed for exceptional quality and consistent delivery."

Veeva predicted that revenue for the year will be between \$404m and \$406m, which is a significant increase on the \$313.2m it generated in fiscal 2015. It also predicted operating income of around \$109m, up from \$40,4m.

Copyright - Unless otherwise stated all contents of this web site are © 2016 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions

RELATED NEWS:

Promeditec moves to Verizon's cloud

Veeva España: Cloud-data firm launches European doctor database

Veeva encouraged to tap CRO industry after inVentiv puts head in the cloud

Veeva aims to boost efficiency with cloud-based data alignment tool

Slowly but surely... CROs gradually shifting to paperless trials, says Veeva

Veeva: eTMF software makes CROs stand out from the cloud

Trial documents: only 13% of firms are fully paperless, says Veeva

Favourite for Novo Nordisk CEO suddenly quits

Who's the next big thing in outsourcing?

Survey finds CROs far from going paperless with TMFs

RELATED TOPICS:

Commercial Services, Regulatory affairs

RELATED PRODUCTS

Seeking Drug Approval via the 505(b)(2) NDA Option

QPS | 07-May-2015 | Technical / white paper Today, many pharmaceutical companies are choosing the 505(b)(2) New Drug Approval (NDA) regulatory pathway. The 505(b)(2) NDA route relie...

in-PharmaTechnologist.com

Pharmaceutical Technology - Daily

Delivery formulations

Delivery technologies

Processing equipment

QA/QC

Regulations

Pharmaceutical Technology - Weekly

APIs (active pharmaceutical ingredients)

Excipients, raw materials and intermediates

Tabletting, coating & ancillary equipment

RELATED SUPPLIERS

Marken QPS

WEEKLY / DAILY FREE NEWSLETTERS

Pharmaceutical Outsourcing - Daily
Pharmaceutical Outsourcing - Weekly

Analytical testing, QC
Contract Manufacturing
Drug delivery, formulation
Fill & finish, packaging

Medical Devices

Phase I-II

Phase III-IV

Preclinical

Regulatory affairs

Supply chain, logistics

BioPharma-Reporter.com NEW!

Biopharmaceutical Development - Daily Biopharmaceutical Development - Weekly

Analytical (technologies & services)

Bioreactors

- Cell lines
- Disposable Manufacturing Tech

Facilities

Fill-Finish & Packaging

Separation & Purification



Johnson & Johnson opens incubator to accelerate early stage research

Colorcon opens Colombia formulation lab

pricing depate wages

Promeditec moves to Verizon's



Teaching old drugs new treatments

cloud

OTHER NEWSLETTERS

Pharma legislation

Pharma finance

Drug targeting and delivery

Reproduced by Gorkana under licence from the NLA (newspapers), CLA (magazines), FT (Financial Times/ft.com) or other copyright owner. No further copying (including printing of digital cuttings), digital reproduction/forwarding of the cutting is permitted except under licence from the copyright owner. All FT content is copyright The Financial Times Ltd.
